In vitro study | In the biochemical tests, cell experiments and mass spectrometry of 347 kinases, CC-90003 strongly inhibited the kinase activity of ERK1 and ERK2, and IC50 had good kinase selectivity at 10-20 nM. In the kinase library containing 258 kinases, CC-90003 inhibited 213 of them by less than 50%, it has moderate inhibitory activity on 28 kinases (50%-80% inhibition) and significant inhibitory effect on 17 kinases (>80%). Kinase screening in A375 cells, a melanoma cell line with the BRAF V600E mutation, showed only five kinases out of 194 (ERK1, ERK2, MKK4, MKK6 and FAK) was significantly inhibited (>80%) by 1 mM CC-90003. The same concentration had no significant inhibitory activity on 40 non-kinase enzymes and receptors (<14%). By iterative analysis, in cells, except ERK1/2, only three kinases were CC-90003 inhibited at biologically relevant concentrations: KDR, FLT3, and PDGFRa. Tumor cells with the BRAF mutation are particularly sensitive to CC-90003. In most (but not all) cases, CC-90003 has toxic effects on PDAC, lung and colon cancer cell lines with KRAS mutations. CC-90003 did not significantly inhibit the proliferation of normal lung fibroblasts or airway epithelial cells. |